BACKGROUND: The pathology and clinical course of patients with CD5+ chronic B-cell lymphoproliferative disorders, excluding those that present with typical chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) or mantle cell lymphoma, (i.e. CD5+B-CLPD) are poorly defined. METHODS: We studied patients with CD5+B-CLPD to (1) more completely define the clinical features and pathology of CD5+B-CLPD, (2) compare these features to patients presenting with typical CLL, and (3) test the hypothesis that a subset of patients with CD5+B-CLPD could have a unique B-cell malignancy. RESULTS: We identified 229 patients with CD5+B-CLPD. A definitive pathological diagnosis was made in all 61 (27%) CD5+B-CLPD patients with nonbone marrow (BM) biopsy specimens considered adequate for a comprehensive pathological examination. The most common diagnosis among these 61 patients was CLL (44%) followed by the leukemic phase of marginal zone lymphoma (34%), lymphoplasmacytic lymphoma (11%), diffuse large B cell lymphoma (8%), and high-grade B cell lymphoma not otherwise specified (2%). In contrast, among 168 patients without a non-BM tissue biopsy specimen, a specific diagnosis could be made on review of all available data in only 24 (14%) with 144 (86%) remaining "unclassified." CONCLUSIONS: In patients with CD5+B-CLPD, a definitive diagnosis can be made on an adequate non-BM tissue biopsy suggesting that this entity does not include a novel disease. We recommend that all patients with CD5+B-CLPD should have a non-BM tissue biopsy to make a definitive diagnosis prior to initiation of treatment.
BACKGROUND: The pathology and clinical course of patients with CD5+ chronic B-cell lymphoproliferative disorders, excluding those that present with typical chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) or mantle cell lymphoma, (i.e. CD5+B-CLPD) are poorly defined. METHODS: We studied patients with CD5+B-CLPD to (1) more completely define the clinical features and pathology of CD5+B-CLPD, (2) compare these features to patients presenting with typical CLL, and (3) test the hypothesis that a subset of patients with CD5+B-CLPD could have a unique B-cell malignancy. RESULTS: We identified 229 patients with CD5+B-CLPD. A definitive pathological diagnosis was made in all 61 (27%) CD5+B-CLPD patients with nonbone marrow (BM) biopsy specimens considered adequate for a comprehensive pathological examination. The most common diagnosis among these 61 patients was CLL (44%) followed by the leukemic phase of marginal zone lymphoma (34%), lymphoplasmacytic lymphoma (11%), diffuse large B cell lymphoma (8%), and high-grade B cell lymphoma not otherwise specified (2%). In contrast, among 168 patients without a non-BM tissue biopsy specimen, a specific diagnosis could be made on review of all available data in only 24 (14%) with 144 (86%) remaining "unclassified." CONCLUSIONS: In patients with CD5+B-CLPD, a definitive diagnosis can be made on an adequate non-BM tissue biopsy suggesting that this entity does not include a novel disease. We recommend that all patients with CD5+B-CLPD should have a non-BM tissue biopsy to make a definitive diagnosis prior to initiation of treatment.
Authors: E J Moreau; E Matutes; R P A'Hern; A M Morilla; R M Morilla; K A Owusu-Ankomah; B K Seon; D Catovsky Journal: Am J Clin Pathol Date: 1997-10 Impact factor: 2.493
Authors: J L Frater; K F McCarron; J P Hammel; J L Shapiro; M L Miller; R R Tubbs; J Pettay; E D Hsi Journal: Am J Clin Pathol Date: 2001-11 Impact factor: 2.493
Authors: Dragan Jevremovic; Roxana S Dronca; William G Morice; Ellen D McPhail; Paul J Kurtin; Clive S Zent; Curtis A Hanson Journal: Leuk Res Date: 2010-04-01 Impact factor: 3.156
Authors: Zachary R Hunter; Andrew R Branagan; Robert Manning; Christopher J Patterson; Daniel Ditzel Santos; Olivier Tournilhac; David M Dorfman; Steven P Treon Journal: Clin Lymphoma Date: 2005-03
Authors: H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter Journal: N Engl J Med Date: 2000-12-28 Impact factor: 91.245
Authors: A Criel; I Wlodarska; P Meeus; M Stul; A Louwagie; A Van Hoof; M Hidajat; C Mecucci; H Van den Berghe Journal: Br J Haematol Date: 1994-07 Impact factor: 6.998
Authors: Gordon W Dewald; Stephanie R Brockman; Sarah F Paternoster; Nancy D Bone; Judith R O'Fallon; Cristine Allmer; Charles D James; Diane F Jelinek; Renee C Tschumper; Curtis A Hanson; Rajiv K Pruthi; Thomas E Witzig; Timothy G Call; Neil E Kay Journal: Br J Haematol Date: 2003-04 Impact factor: 6.998
Authors: E Matutes; D Oscier; J Garcia-Marco; J Ellis; A Copplestone; R Gillingham; T Hamblin; D Lens; G J Swansbury; D Catovsky Journal: Br J Haematol Date: 1996-02 Impact factor: 6.998